Details of mutations found according to antiretroviral family and period of study.

* Only mutations found in at least one case according to WHO list of TDR are listed.& E138A mutation, not listed by WHO 2009 list but associated to rilpivirine resistance was detected in 4 patients (2.1%), 3 (5.4%) in the 2005–2008 period and 1 (1.6%) in the 2009–2012 period.NRTI: Nucleoside/nucleotide reverse transcriptase inhinitorsNNRTI: Non-nucleoside reverse transcriptase inhibitorsPI: Protease inhibitorsDetails of mutations found according to antiretroviral family and period of study.仅收录世界卫生组织（WHO）传播性耐药（Transmitted Drug Resistance, TDR）名录中至少在1例病例中被检出的突变。E138A突变未被纳入2009年版WHO TDR名录，但与利匹韦林（rilpivirine）耐药性相关，该突变共在4例患者中检出，占总病例的2.1%；其中2005–2008年间检出3例，占该时段病例的5.4%，2009–2012年间检出1例，占该时段病例的1.6%。NRTI：核苷类/核苷酸类逆转录酶抑制剂（Nucleoside/nucleotide reverse transcriptase inhibitors）；NNRTI：非核苷类逆转录酶抑制剂（Non-nucleoside reverse transcriptase inhibitors）；PI：蛋白酶抑制剂（Protease inhibitors）。本数据集包含依据抗反转录病毒药物类别及研究时段统计的突变检出详情。